StockOtters
StockOttersSupply Chain Map
WuXi Biologics (Cayman) Inc. logo

WuXi Biologics (Cayman) Inc.

WXXWY

Financial Statements

Income Statement (Annual)

Amounts in millions

2024

12/31/2024

Revenue
2,615
Cost of Revenue
1,543
Gross Profit
1,071
Gross Margin
41.0%
Operating Income
696
Operating Margin
26.6%
Net Income
470
Net Margin
18.0%
EPS (Basic)
$1.56
EPS (Diluted)
$1.56
EBITDA
900
EBITDA Margin
34.4%

2023

12/31/2023

Revenue
2,385
Cost of Revenue
1,429
Gross Profit
956
Gross Margin
40.1%
Operating Income
623
Operating Margin
26.1%
Net Income
476
Net Margin
20.0%
EPS (Basic)
$1.64
EPS (Diluted)
$1.54
EBITDA
770
EBITDA Margin
32.3%

2022

12/31/2022

Revenue
2,138
Cost of Revenue
1,196
Gross Profit
941
Gross Margin
44.0%
Operating Income
609
Operating Margin
28.5%
Net Income
619
Net Margin
29.0%
EPS (Basic)
$2.12
EPS (Diluted)
$2.02
EBITDA
710
EBITDA Margin
33.2%

2021

12/31/2021

Revenue
1,441
Cost of Revenue
765
Gross Profit
676
Gross Margin
46.9%
Operating Income
446
Operating Margin
31.0%
Net Income
474
Net Margin
32.9%
EPS (Basic)
$1.62
EPS (Diluted)
$1.54
EBITDA
507
EBITDA Margin
35.2%

2020

12/31/2020

Revenue
786
Cost of Revenue
431
Gross Profit
355
Gross Margin
45.1%
Operating Income
210
Operating Margin
26.8%
Net Income
236
Net Margin
30.1%
EPS (Basic)
$0.86
EPS (Diluted)
$0.80
EBITDA
248
EBITDA Margin
31.6%